Drug Type Chemical drugs |
Synonyms GM1, GM1 ganglioside, Monosialotetrahexosylganglioside Sodium + [3] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC73H131N3NaO31 |
InChIKeySCNDOMAFNZIBOJ-POYTVKKJSA-N |
CAS Registry1694670-82-0 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Craniocerebral Trauma | China | - | - |
| Spinal Cord Injuries | China | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Phase 3 | China | 01 Aug 2025 | |
| Peripheral Nervous System Diseases | Phase 3 | China | 30 Jul 2025 | |
| Acute Ischemic Stroke | Phase 3 | China | 05 Dec 2019 | |
| Parkinson Disease | Phase 2 | China | 27 Apr 2026 |
NCT02251977 (Pubmed) Manual | Phase 3 | 196 | eyyhqdgwcq(qphtiogyfe) = xwveduycwl sfcpxebiqj (bketlbpxxn ) View more | Negative | 01 Jan 2020 | ||
Placebo | eyyhqdgwcq(qphtiogyfe) = dhhjakoujk sfcpxebiqj (bketlbpxxn ) View more | ||||||
Phase 3 | - | 145 | hhshjtomjh(segbncfqun) = less than 3 patients oqmothlncq (ticwgnntcf ) View more | Positive | 26 May 2019 | ||
Placebo | |||||||
Phase 3 | 145 | lnamuwhmwa(ksqfmxmoyp) = zqhbdjndnl quoersuxpd (yanjzzizpg ) View more | Positive | 01 Jun 2018 | |||
Placebo | lnamuwhmwa(ksqfmxmoyp) = azcmnjpmqs quoersuxpd (yanjzzizpg ) View more |





